Two clinical trials are now underway that look past the question of whether GLP-1 drugs work and toward what happens around them. One asks whether semaglutide can help people with kidney disease move more, not just weigh less. The other asks what happens to your body after you stop the injections. For patients thinking about starting, staying on, or eventually stopping these medications, both studies speak directly to questions your doctor may not yet have answers for.
The Sit Less, Interact and Move More study is a federally funded Phase 2 trial now recruiting people who have both kidney disease and obesity. Researchers want to know whether pairing semaglutide with resistance training changes how much people sit and how much they move during the day, not simply what happens on the scale. This matters because kidney disease can limit physical activity in ways that weight loss drugs alone may not address. If you have kidney disease and are considering semaglutide, this trial may eventually offer evidence about whether adding structured exercise changes your daily function, not just your weight.
The second trial, a small Phase 4 study, has not yet started recruiting and looks at a question many patients ask once they consider stopping GLP-1 injections: will the weight come back. Researchers plan to test whether switching to oral weight management pills after stopping a GLP-1 shot can prevent that regain. The catch is timing. Results are not expected until 2031, so anyone stopping a GLP-1 drug today will not have this trial's findings to guide that decision for several years. In the meantime, the existence of the study itself signals that researchers see weight regain after discontinuation as a real and unresolved problem worth studying formally.
Neither trial will change clinical practice soon, but both point to where the research is heading: past initial weight loss and into the practical questions of daily function and long-term maintenance. If you are currently on a GLP-1 medication or considering one, it may be worth asking your doctor directly about exercise recommendations during treatment, and separately, about what a realistic plan looks like if you ever decide to stop. Keep an eye on this tracker for updates as these trials progress or as related research is published.
Key details
A federally funded trial is recruiting kidney disease and obesity patients to test…
A small trial will test if oral pills prevent weight regain after stopping GLP-1 shots,…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-01